Calithera Biosciences, Inc. (CALA)
| Market Cap | 22.55M |
| Revenue (ttm) | 9.75M |
| Net Income (ttm) | -108.53M |
| Shares Out | 97.24M |
| EPS (ttm) | -1.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,157,348 |
| Open | 0.210 |
| Previous Close | 0.208 |
| Day's Range | 0.205 - 0.235 |
| 52-Week Range | 0.154 - 2.593 |
| Beta | 1.62 |
| Analysts | Buy |
| Price Target | 2.42 (+943.6%) |
| Earnings Date | May 10, 2022 |
About CALA
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chro...
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for CALA stock is "Buy." The 12-month stock price forecast is 2.42, which is an increase of 943.55% from the latest price.
News
Calithera to Present at the H.C. Wainwright Global Investment Conference
SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molin...
Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
-- Conference Call and Webcast Scheduled for 2:00 p.m. PT / 5:00 p.m. ET on Tuesday, May 10, 2022 -- SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CA...
Calithera Biosciences to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022
SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Company...
Best Penny Stocks to Buy Under $1 Now? 3 to Watch in May
Are these under $1 penny stocks on your watchlist right now? The post Best Penny Stocks to Buy Under $1 Now?
Calithera Presents Data Highlighting Discovery of Novel Series of Promising Synthetic Lethal Compounds
Findings presented today at AACR Annual Meeting detail Calithera discovery of VPS4A inhibitors and their potential as a therapeutic approach in numerous solid tumor cancers
Calithera Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
Conference Call and Webcast Scheduled for 2:00 p.m. PT / 5:00 p.m. ET on Thursday, March 31, 2022 Conference Call and Webcast Scheduled for 2:00 p.m. PT / 5:00 p.m. ET on Thursday, March 31, 2022
Calithera Biosciences Raises $10M Via Equity Issued At 10% Discount
Calithera Biosciences Inc (NASDAQ: CALA) priced its previously announced underwritten public offering of 18.5 million shares at $0.54 per share for gross proceeds of $10 million. Each share of common st...
Calithera Biosciences, Inc. Prices $10.0 Million Underwritten Public Offering of Common Stock and Warrants to Purchas...
SOUTH SAN FRANCISCO, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced the pricing of...
Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock and Warrants to Pu...
SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that it intend...
3 Hot Meme Penny Stocks to Watch Under $3 Right Now
Can these meme penny stocks under $3 make you money next month? The post 3 Hot Meme Penny Stocks to Watch Under $3 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto...
Calithera Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 31, 2022
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Compa...
Calithera to Present Data Highlighting Newly Discovered Synthetic Lethal Target VPS4 at AACR 2022 Annual Meeting
First data from preclinical synthetic lethality program of novel VPS4A inhibitors with potential for clinical advancement in variety of cancers First data from preclinical synthetic lethality program of...
Calithera to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Moli...
AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease Pro...
MENLO PARK, Calif., Jan. 7, 2022 /PRNewswire/ -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases wi...
Calithera to Present at the H.C. Wainwright BioConnect Virtual Conference
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Moli...
Do Options Traders Know Something About Calithera Biosciences (CALA) Stock We Don't?
Investors need to pay close attention to Calithera Biosciences (CALA) stock based on the movements in the options market lately.
Calithera to Present at the 2021 Jefferies London Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Moli...
Calithera Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights
-- Company strengthened precision oncology clinical pipeline through acquisition of mTORC 1/2 inhibitor sapanisertib and SYK inhibitor mivavotinib from Takeda Pharmaceuticals -- -- Cash, cash equivalent...
Why Did Calithera Shares Dropped To 52-Week Low In Premarket Friday?
Calithera Biosciences Inc (NASDAQ: CALA) has decided to terminate its phase 2 KEAPSAKE trial based on a lack of clinical benefit observed in patients treated with telaglenastat in an interim analysis. T...
Calithera Biosciences Promotes Emil T. Kuriakose, MD, to Chief Medical Officer
-- Dr. Kuriakose to succeed Keith Orford, MD, PhD, who will assume seat on Calithera Board of Directors -- Dr. Kuriakose to succeed Keith Orford, MD, PhD, who will assume seat on Calithera Board of Dire...
Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial
--KEAPSAKE interim analysis demonstrated lack of clinical benefit among patients treated with telaglenastat
Calithera Biosciences to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Compan...
Calithera Posts Early-Data For Arginase Inhibitor In Cystic Fibrosis Trial
Calithera Biosciences Inc (NASDAQ: CALA) shared interim safety and efficacy results from a Phase 1b trial evaluating CB-280, the company's investigational arginase inhibitor, in adults with cystic fibro...
Calithera Presents Interim Data from Phase 1b Trial of Arginase Inhibitor CB-280 in Cystic Fibrosis at NACFC 2021
-- CB-280 was well-tolerated, showed linear PK and demonstrated robust dose-related PD effects -- Encouraging trends seen in disease biomarkers including increased FeNO and decreased sweat chloride -- E...
Calithera Biosciences to Present First Clinical Data from Development Program for Arginase Inhibitor CB-280 at NACFC ...
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biopharmaceutical company, today announced that data from its Phase 1b trial o...